Last reviewed · How we verify
Filgrastim (Eurofarma)
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil progenitor cells in bone marrow.
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil progenitor cells in bone marrow. Used for Chemotherapy-induced neutropenia, Severe chronic neutropenia, Mobilization of peripheral blood progenitor cells for autologous transplantation.
At a glance
| Generic name | Filgrastim (Eurofarma) |
|---|---|
| Sponsor | Eurofarma Laboratorios S.A. |
| Drug class | Granulocyte colony-stimulating factor (G-CSF) |
| Target | G-CSF receptor (CSF3R) |
| Modality | Small molecule |
| Therapeutic area | Oncology, Hematology |
| Phase | Phase 3 |
Mechanism of action
Filgrastim binds to G-CSF receptors on hematopoietic cells, promoting the growth and maturation of neutrophils from bone marrow precursors. This increases circulating neutrophil counts, helping to reduce the risk and duration of infection in patients with chemotherapy-induced neutropenia or other conditions causing low white blood cell counts.
Approved indications
- Chemotherapy-induced neutropenia
- Severe chronic neutropenia
- Mobilization of peripheral blood progenitor cells for autologous transplantation
Common side effects
- Bone pain
- Headache
- Fatigue
- Injection site reactions
- Splenomegaly
- Elevated uric acid
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Filgrastim (Eurofarma) CI brief — competitive landscape report
- Filgrastim (Eurofarma) updates RSS · CI watch RSS
- Eurofarma Laboratorios S.A. portfolio CI